Metastatic / secondary lung cancer, explained simply

Metastatic lung cancer is used in two ways. It can mean a lung cancer that began in the lung and has spread to other parts of the body, which is often called advanced or stage IV lung cancer. It can also mean a cancer that started in another organ — such as the breast, colon, or kidney — and has spread to the lungs. In that second case the lung tumours are called secondary lung cancer or lung metastases. The difference matters because treatment follows where the cancer started, not simply where it is now. Confirming the origin with scans and a biopsy is the first step in shaping the right plan.

Primary lung cancer starts in the cells of the lung itself. Secondary lung cancer, also called metastatic disease in the lungs, is cancer that began somewhere else in the body and spread to the lungs. Even though both involve tumours in the lungs, they are made of different cells. Secondary tumours are made of the same cells as the original cancer, so cancer that spread from the breast is still treated as breast cancer. This is why the very first thing your team confirms — usually with a biopsy — is where the cancer truly started, because it decides the entire treatment approach.

Cancer cells can break away from the original tumour and travel through the bloodstream or the lymphatic system to other parts of the body. The lungs are one of the most common places for this to happen, because all of the body's blood passes through them and they have a rich network of small vessels. When cancer cells settle and grow in the lungs, they form secondary tumours, or lung metastases. This process is called metastasis. It does not mean the cancer is untreatable — it means treatment is now directed at controlling the cancer throughout the body, guided by where it started and its biomarkers.

Lung metastases do not always cause symptoms early, and many are first found on a scan done for another reason. When symptoms appear, they can include a new or changing cough, breathlessness, chest pain, or coughing up blood. Whole-body signs such as tiredness, loss of appetite, or unexplained weight loss can also occur. If the cancer has spread beyond the lungs, there may be symptoms from those sites too, such as bone pain or headaches. These symptoms overlap with many harmless conditions, so they are reasons to get checked rather than reasons to assume the worst. Only proper testing can tell them apart.

Diagnosis usually begins with imaging — a CT scan, and often a whole-body PET-CT — to show where the tumours are and how far the cancer has spread. Scans can suggest where the cancer started, but they cannot confirm it; that needs tissue. So a biopsy is taken from a lung tumour or another accessible site and examined under a microscope. This confirms whether it is a primary lung cancer or a secondary deposit and identifies the cell type. The tissue is then tested for biomarkers, such as EGFR, ALK, or PD-L1. At CION, the full picture is reviewed by a multidisciplinary tumour board before a plan is agreed.

Treatment is chosen by where the cancer started, its biomarkers, and how widely it has spread, and it often combines more than one approach. For metastatic lung cancer, options include targeted therapy matched to a gene change such as EGFR or ALK, immunotherapy, chemotherapy, and radiation to treat limited spread or ease symptoms. Supportive and palliative care runs alongside from the start to control symptoms and protect quality of life. When the lungs are a secondary site, treatment is directed at the original cancer type. At CION, every plan is agreed by a tumour board so it reflects the combined judgement of medical, surgical, and radiation oncologists.

Biomarker, or molecular, testing examines the biopsy tissue for specific gene changes and proteins. In metastatic lung cancer, certain changes — such as EGFR, ALK, ROS1, and others — can be matched to targeted drugs that act on those exact changes, and PD-L1 levels can help guide whether immunotherapy may help. This means treatment can be tailored rather than one-size-fits-all, and it sometimes opens up options that the stage alone would not reveal. Because these results can meaningfully change the recommended treatment, biomarker testing is now a routine and important part of the work-up for metastatic disease.

Yes. Metastatic disease is serious, but it is not the end of the road. The aim of treatment shifts towards controlling the cancer throughout the body, easing symptoms, and protecting quality of life, often for a long time. Modern treatments — targeted therapy, immunotherapy, chemotherapy, and precise radiation — can do this effectively for many people, and the options have grown considerably in recent years. For a small number of people with very limited spread, called oligometastatic disease, more focused treatment of the few sites may be possible. The right approach depends on your cancer type, biomarkers, and overall health, which is why each plan is individualised.

The outlook is not a single number that applies to everyone. It depends on the type of cancer and where it started, the biomarkers found on testing, how widely the cancer has spread, and a person's overall health and fitness. In recent years, targeted therapy and immunotherapy have meaningfully improved what is possible for some people with metastatic disease compared with the past. This is exactly why molecular testing of the biopsy is so important — it can reveal options that the words metastatic or stage IV alone would not. No website can tell you your own outlook; only your team can, after reviewing your cancer type, biomarkers, and spread together in an unhurried consultation.

Seeking a second opinion is reasonable and common, especially for a diagnosis as significant as metastatic or secondary lung cancer. A second opinion can confirm where the cancer started, check that biomarker testing has been done, and make sure all suitable treatment options have been considered. It does not delay care in most situations, and it can bring real peace of mind. At CION, the first 45-minute consultation is free and doctor-led, and includes a written second opinion. You are under no obligation to start treatment — the aim is simply to give you a clear, honest picture so you can make a decision you feel settled with.